Navigation Links
Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
Date:10/1/2007

stop eating," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "The Phase 2 trial that we are initiating is designed to demonstrate the effectiveness of PYY nasal spray in promoting weight loss which, if successful in development and approval, could help treat what has become an international health epidemic affecting hundreds of millions of people worldwide."

About PYY

Peptide YY is a naturally occurring hormone that is believed to function as a physiologic inhibitor of food intake. PYY is released into the blood stream from specialized endocrine cells (L-cells) in the gut after a meal and is believed to trigger the feeling of satiety, or fullness. Because PYY is a peptide, initial studies focused on PYY delivery by injection. Utilizing its proprietary drug delivery technology, Nastech developed the nasal spray formulation of PYY as a unique, non-invasive treatment option for obesity.

About Obesity

There are approximately 1.6 billion overweight adults worldwide, 400 million of whom are clinically obese according to World Health Organization. Obesity contributes to increased risk for chronic diseases including type 2 diabetes, cardiovascular disease and hypertension. PYY nasal spray may offer a novel treatment option for those suffering from this condition.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.

Nastech Forward Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subj
'/>"/>

SOURCE Nastech Parmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
(Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
Breaking Medicine Technology:Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
... Calif., March 7, 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ... 1 study of ISIS-STAT3Rx, a Generation 2.5 antisense drug ... of signal transducer and activator of transcription 3 (STAT3). ... cancers, ISIS-STAT3Rx has the potential to be broadly useful ...
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
Cached Medicine Technology:Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 2Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 3Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 4Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4
(Date:7/31/2014)... (PRWEB) July 31, 2014 Cheerag ... experienced, sub-specialty trained neurosurgeons at the Saint Luke’s ... Spine Program and director of spine surgery. He comes ... Wash. , “Dr. Upadhyaya has been recognized for his ... complex spine issues. His addition to the Saint Luke’s ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 What’s ... practice provider? Community Health Center of Snohomish answers ... Pediatricians vs. Family Doctors ”. Many adults can ... available to them. Community Health Center hopes to ... and differences between the two. , To ...
(Date:7/31/2014)... Bellava MedAesthetics is proud to introduce ... surgeon! , Dr. Kim has more than a ... the look of their dreams. He focuses on natural ... augmentation (including Gummy Bear implants ), laser liposuction, ... Brazilian butt lift), abdominoplasty (tummy tuck), rhinoplasty, blepharoplasty (eyelid ...
(Date:7/31/2014)... 2014 When it comes to aesthetics ... and improve. As such, Natalie Sharp's Pure Vitality ... for a new, more focused direction and to provide ... patients! , Pure Vitality Rx is Oyster Bay's premier ... wide variety of services primarily dedicated to women. Services ...
(Date:7/31/2014)... Boston, MA (PRWEB) July 31, 2014 Many ... fight for the weak, to correct injustices, and preserve the ... - action that can be lauded as crusading and exemplary ... the lawyer takes on corruption whose seed might be planted ... a fury and the ultimate punishment for an attorney - ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4Health News:Community Health Center of Snohomish County Reveals the Differences Between Pediatricians and Family Practice Providers 2Health News:Bellava MedAesthetics Welcomes Dr. Chang Soo Kim as Its New Westchester Plastic Surgeon 2Health News:Natalie Sharp's Pure Vitality Rx Upgrade - Partnership With Shangri-La Spa and Website Facelift! 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 3
... Carolina at Chapel Hill researchers published a study that found ... to have Parkinson,s disease than people with high LDL levels. ... whether low LDL (low-density lipoprotein) levels were present in study ... developed low LDL levels after being diagnosed. , Now a ...
... 4, 2008 Smart Balance,Inc. (Nasdaq: SMBL ) ... been named to the position of vice president, business,development. ... vice president,general manager, Midwest. Brett Meltzer has been named ... three are new employees of the,Company., "I am ...
... raises prospect of new treatment for tick-borne diseases in ... injection of a long-acting version of the antibiotic doxycycline ... Lyme disease or anaplasmosis, new animal research reveals. , ... raises hope for developing a safer and more effective ...
... & Research (NTMir), a,Miami, Florida based not-for-profit organization, ... been awarded to the Research,Institute of the McGill ... Genome Sequence of Mycobacterium avium intracellulare.", The ... NTMir in its innovative,research initiative, Rapid Information Pilot ...
... Business and,Disrupt Services to as Many as a Half ... April 4, 2008 A new Medicare,bidding program for ... Cincinnati and Cleveland, Ohio areas on July 1, 2008,will ... likely disrupt,services for many of the 540,000 seniors and ...
... A promising vaccine being tested for Alzheimer,s disease does ... plaques from the brain -- but it does not ... according to a University of California, Irvine study. , ... Alzheimer,s disease -- beta-amyloid plaques -- by itself may ...
Cached Medicine News:Health News:Pieces coming together in Parkinson's, cholesterol puzzle 2Health News:Smart Balance Announces Sales Organization Appointments 2Health News:Smart Balance Announces Sales Organization Appointments 3Health News:Injectable Antibiotic Protects Against Lyme Disease in Mice 2Health News:Injectable Antibiotic Protects Against Lyme Disease in Mice 3Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 2Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 3Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 4Health News:Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment 2
Printed with large 20/200 E on one side and a series of five 20/20 tumbling Es on the other- calibrated to a 20 ft. distance. May be used to test and train peripheral awareness....
... 2/25 is an economically priced 2-channel ... and research use in the fields ... neurophysiology, biology, zoology, biochemistry and biomedical ... ADInstruments signal conditioners and transducers. Two ...
... The PowerLab/4SP is a high-performance data ... of research applications including human and animal ... biomedical engineering. The unit is capable of ... speeds (up to 200 000 samples per ...
... Worth 4 Dot with 955R Red/Green ... the presence of binocular vision. Consists ... illuminated discs: two green, one red ... at any distance. Patient wears red/green ...
Medicine Products: